Saudi-Emirati Global Fertility Network Acquires HealthPlus in Jeddah

The Saudi-Emirati Global Fertility Network (GFN) has acquired a majority stake in HealthPlus Fertility Center in Jeddah, expanding its presence in Saudi Arabia’s growing women’s health sector. The facility will be rebranded under the Bnoon IVF name, following GFN’s earlier acquisition of Bnoon IVF Center in Riyadh. Together, the two acquisitions represent an investment of over 100 million Saudi Riyals (approximately $27 million), forming the foundation of GFN’s strategy to establish the largest fertility care network in Saudi Arabia and the wider GCC. Both HealthPlus and Bnoon IVF previously operated under M42’s healthcare portfolio between 2022 and 2024.

“We’re seeing a noticeable increase in couples seeking fertility treatment, driven by both primary and secondary infertility,” Dr. Abdulaziz Muhammad AlShahrani, a leading Saudi Reproductive Endocrinology & Infertility (IVF) Consultant, Founder of Bnoon in Riyadh and the Group Medical Director at Bnoon, said. “With growing awareness, more individuals are also considering fertility treatments to help balance their families and prevent genetic diseases." With these new additions, GFN has doubled its treatment capacity and now conducts more than 5,000 IVF cycles annually, making it the largest standalone provider of assisted reproductive services in the Kingdom.

“We have identified a strong pipe-line of potential targets for acquisition across the region," Majd Abu Zant, Founder and CEO of Global Fertility Network, said. "New IVF facilities are also planned in Khobar, Abha, and additional cities across the Kingdom. With the support of our investment partners, we will continue to rapidly expand our network while introducing cutting-edge technologies faster, enhancing clinical outcomes, and making fertility care more accessible across the region.” GFN is also constructing a 3,800-square-metre flagship centre in northern Riyadh, set to open in December 2025. The facility will focus on advanced fertility treatment and reproductive genetics, and will form part of a broader integrated women’s health offering across the network.